HALIFAX, Oct. 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today
that it is broadening its US patent portfolio with new filings related to the
Company's rapid flow-through technology, the core innovation behind its rapid
diagnostics. In order to strengthen its overall IP position, the Company has
also filed for continued examination on its original US patent application
that was allowed in July 2008.
